Platform and Pipeline - Unum Therapeutics' ACTR/BOXR platforms are designed to improve targeting and functionality of T cell therapies[5,8] - The company is advancing a pipeline of product candidates in hematologic cancers and solid tumors, including ACTR707, ACTR087, and BOXR1030[6] - BOXR platform addresses the tumor microenvironment (TME) challenge by improving T cell functionality[14,15] Clinical Trial Results (ACTR707 in r/r NHL) - Preliminary Phase 1 trial data for ACTR707 in relapsed/refractory (r/r) Non-Hodgkin's Lymphoma (NHL) showed an overall response rate (ORR) of 64% (9/14 patients) across Cohorts 1-3[25] - Complete responses (CR) were observed in 36% of patients (5/14) across Cohorts 1-3[25] - The trial showed a favorable safety profile with no dose-limiting toxicities (DLTs), severe neurologic events, or Cytokine Release Syndrome (CRS) observed in Cohorts 1-3[27] Clinical Trial Results (ACTR087 in Multiple Myeloma) - Phase 1 trial of ACTR087 in multiple myeloma completed three dose levels in 2018 at very low antibody doses and 30M ACTR+ T cells, with no dose-limiting toxicities or severe CRS or neurologic events observed[33] Solid Tumor Programs - ACTR707 is also being evaluated in a Phase 1 trial for advanced HER2+ cancers[6,37] - BOXR1030, a GPC3-targeted CAR-T, is engineered for enhanced metabolism in the solid tumor microenvironment and has shown promising preclinical activity[39,42] Upcoming Milestones - Several milestones are anticipated in 4Q 2019, including reporting preliminary Cohort 3 results and Cohort 1-4 results from ATTCK-20-03, reporting safety and efficacy results from Phase 1 (ATTCK-20-02), reporting enrollment status and safety in Phase 1 (ATTCK-34-01), progress BOXR-1030 towards IND[43]

Unum Therapeutics Inc. (UMRX) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Corporate Participants Chuck Wilson - Chief Executive Officer Jessica Sachs - Chief Medical Officer Seth Ettenberg - Chief Scientific Officer Matt Osborne - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Peter Lawson - SunTrust Robinson Leo Li - Cowen Operator Good afternoon, and welcome to the Unum Therapeutics' Quarterly Investor Conference Call. Today, we will be showing update ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------- ...

Unum Therapeutics Inc. (UMRX) Q1 2019 Results Earnings Conference Call May 13, 2019 8:00 AM ET Company Participants Stephanie Ascher - Investor Relations Chuck Wilson - Chief Executive Officer John Green - Vice President of Finance Michael Vasconcelles - Chief Medical Officer Seth Ettenberg - Chief Scientific Officer Conference Call Participants Peter Lawson - SunTrust Yaron Werber - Cowen Operator Good day, ladies and gentlemen, and welcome to the Unum Therapeutics' First Quarter 2019 Results Conference Ca ...

Table of Contents Emerging growth company ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38443 UNUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) D ...

Unum Therapeutics Inc. (UMRX) Q4 2018 Results Earnings Conference Call March 28, 2019 8:00 AM ET Company Participants Stephanie Ascher - Investor Relations Chuck Wilson - Chief Executive Officer John Green - Vice President of Finance Michael Vasconcelles - Chief Medical Officer Seth Ettenberg - Chief Scientific Officer Conference Call Participants Peter Lawson - SunTrust Robinson Humphrey David Nierengarten - Wedbush Securities Operator Good day, ladies and gentlemen, and welcome to the Unum Therapeutics' F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-----------------------------------------------------------------------------|----------------------------------------------------------------------- ...

UNUM THERAPEUTICS CORPORATE PRESENTATION MARCH 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed forward-looking, i ...